The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Henry L. Gomez

Henry L. Gómez

Department of Medicine

Instituto Nacional de Enfermedades Neoplásicas

Av. Angamos Este 2520

[email]@inen.sld.pe

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Henry L. Gómez, Department of Medicine, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520. 2011 - 2012
  • Instituto Nacional de Enfermedades Neoplásicas, Peru. 2006 - 2010

References

  1. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Gómez, H.L., Samanéz, C., Campana, F., Neciosup, S.P., Vera, L., Casanova, L., Leon, J., Flores, C., de Mendoza, F.H., Casteñeda, C.A., Pinto, J.A., Vallejos, C.S. Hematol. Oncol. Stem. Cell. Ther (2012) [Pubmed]
  2. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Gómez, H.L., Pinto, J.A., Olivera, M., Vidaurre, T., Doimi, F.D., Vigil, C.E., Velarde, R.G., Abugattas, J.E., Alarcón, E., Vallejos, C.S. Breast (2011) [Pubmed]
  3. Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Gómez, H.L., Castañeda, C.A., Vigil, C.E., Vidaurre, T., Velarde, R.G., Cruz, W.R., Pinto, J.A., Suazo, J.F., Garcés, M.R., Neciosup, S.P., Vallejos, C.S. Hematol. Oncol. Stem. Cell. Ther (2010) [Pubmed]
  4. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. Gomez, H.L., Doval, D.C., Chavez, M.A., Ang, P.C., Aziz, Z., Nag, S., Ng, C., Franco, S.X., Chow, L.W., Arbushites, M.C., Casey, M.A., Berger, M.S., Stein, S.H., Sledge, G.W. J. Clin. Oncol. (2008) [Pubmed]
  5. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Gomez, H.L., Santillana, S.L., Vallejos, C.S., Velarde, R., Sanchez, J., Wang, X., Bauer, N.L., Hockett, R.D., Chen, V.J., Niyikiza, C., Hanauske, A.R. Clin. Cancer Res. (2006) [Pubmed]
 
WikiGenes - Universities